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Background: Pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment of
metastatic breast cancer (MBC). We carried out a multicenter, single-arm phase II trial to evaluate the toxicity and
efficacy of PLD and bevacizumab as first-line treatment in MBC patients.
Methods: Bevacizumab (10 mg/kg) and PLD (20 mg/m2) were infused on days 1 and 15 of a 4-week cycle for
a maximum of six cycles. Thereafter, bevacizumab monotherapy was continued at the same dose until progression or
toxicity. The primary objective was safety and tolerability, and the secondary objective was to evaluate efficacy of the
combination.
Results: Thirty-nine of 43 patients were assessable for the primary end point. Eighteen of 39 patients (46%, 95%
confidence interval 30% to 63%) had a grade 3 toxicity. Sixteen (41%) had grade 3 palmar-plantar erythrodysesthesia,
one had grade 3 mucositis, and one severe cardiotoxicity. Secondary end point of overall response rate among 43
assessable patients was 21%.
Conclusions: In this nonrandomized single-arm trial, the combination of bimonthly PLD and bevacizumab in locally
recurrent and MBC patients demonstrated higher than anticipated toxicity while exhibiting only modest activity. Based
on these results, we would not consider this combination for further investigation in this setting.
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introduction
Breast cancer is the most common cancer in women worldwide,
with the highest rate of occurrence in Western Europe and
North America. It has been estimated that in 2006, there were
429 900 new breast cancer cases in Europe (28.9% of all new
cancers) and 131 900 breast cancer deaths (7.8% of all cancer-
related deaths) [1]. Five-year survival rates for women with any
stage of breast cancer are estimated at 80% [2]. Once
metastatic disease is detected, median survival ranges between
24 and 30 months [3]. Many improvements have been made in
the treatment of metastatic breast cancer (MBC) over the past 5
years, including integration of targeted and biologic agents, new
cytotoxic agents, and novel combinations and sequential drug
administration. Few regimens have translated into an
incremental gain in overall survival (OS) for these patients.
Despite new discoveries, anthracyclines continue to be
a mainstay for the treatment of MBC. Pegylated liposomal
doxorubicin (PLD; Caelyx, Schering-Plough/Merck) is a novel
formulation of doxorubicin. PLD’s unique formulation of
doxorubicin, encapsulated within liposomes coated with
polyethylene glycol, results in prolonged circulation time and
decreased cardiotoxicity, alopecia, and myelosuppression,
providing an enhanced therapeutic index [4–6]. The side-effect
profile of PLD includes mucositis, hand–foot syndrome, and
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mild myelosuppression [5, 6]. A phase III trial of PLD versus
doxorubicin as first-line therapy for MBC showed comparable
efficacy between the two agents, with reduced cardiotoxicity in
the PLD-treated arm [6].
Bevacizumab (Avastin; F. Hoffmann–la Roche Ltd, Basel,
Switzerland) is a recombinant humanized monoclonal antibody
to the human vascular endothelial growth factor (VEGF)-A that
blocks the binding of human VEGF-A to its receptors. Clinical
activity of bevacizumab–chemotherapy combinations has been
demonstrated in randomized controlled trials in non-small-cell
carcinoma of the lung, colorectal, and renal cell carcinoma [7–
9]. In a randomized phase III trial in first-line MBC,
bevacizumab in combination with paclitaxel significantly
improved response rate (RR) and progression-free survival
(PFS) but not OS [10]. The addition of bevacizumab was
relatively well tolerated and added only few grade 3 and grade 4
treatment-associated toxic effects. Two as yet unpublished large
randomized studies of chemotherapy versus chemotherapy plus
bevacizumab in MBC, AVADO, and RIBBON-1 also
demonstrate substantially increased RRs and improved PFS
when bevacizumab was added to a taxane, anthracycline, or
capecitabine [11, 12].
When the trial was initiated, limited data on the combination
of bevacizumab and anthracyclines suggested potential for
additive toxicity, including cardiac dysfunction [13–15]. In
a phase II trial, evaluating the combination of doxorubicin and
bevacizumab in patients with metastatic soft tissue sarcoma,
conventional doxorubicin was shown to be associated with
unacceptable cardioxicity [13]. Subsequently, PLD was
substituted for conventional doxorubicin and evaluated in
combination with bevacizumab in sarcoma patients [14].
Mucositis and skin toxic effects were dose limiting with the
combination using a PLD dose of 45–50 mg/m2 every 4 weeks.
Therefore, a PLD dose reduction to 22.5 mg/m2 every 2 weeks
was implemented and recommended for future trial of the
combination [14]. We initiated a multicenter, single-arm
phase II trial to evaluate the toxicity and efficacy of
PLD and bevacizumab as first-line treatment for patients
with MBC.
methods
patients
Eligible patients had cytologically or histologically proven metastatic or
locally recurrent inoperable erbB2-negative breast cancer. Other inclusion
criteria included tumor not amenable to radiotherapeutic treatment,
measurable disease according to RECIST criteria [16], left ventricular
ejection fraction (LVEF) ‡55%, World Health Organization performance
status zero or one, no previous chemotherapy for metastatic or
inoperable locally recurrent breast cancer, and low-risk factors for
bleeding (e.g. normal coagulation parameters, no concomitant treatment
with anticoagulants, sufficient interval from surgical procedures).
Exclusion criteria included previous adjuvant or neoadjuvant
chemotherapy within 12 months before registration; previous therapy
with bevacizumab or other anti-VEGF drug; cumulative doxorubicin dose
of >360 mg/m2 or epirubicin >720 mg/m2; epirubicin as neoadjuvant or
adjuvant treatment; known central nervous system (CNS) metastases;
severe cardiovascular disease; tumor amenable to radiotherapy; or history
of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess.
trial design
SAKK (Schweizerische Arbeitsgemeinschaft Klinische Krebsforschung)
sponsored this prospective, single-arm, multicenter phase II trial of
bevacizumab in combination with PLD in patients with inoperable locally
recurrent or MBC. Patients were treated with PLD 20 mg/m2 i.v. on days 1
and 15 of each 4-week cycle for a maximum of six cycles or until an event
qualifying for discontinuation occurred. Patients received bevacizumab 10
mg/kg i.v. on days 1 and 15 of each 4-week cycle for six cycles in
combination with PLD and as monotherapy thereafter. PLD and/or
bevacizumab were to be discontinued for progressive disease (PD),
unacceptable adverse reaction, patient refusal, or physician withdrawal.
The primary end points were severe cardiac toxicity or grade 4/5 and
selected grade 3 nonhematological toxicity of the treatment combination.
Severe cardiac toxicity was defined as symptomatic deterioration to New
York Heart Association (NYHA) III or IV; concomitant with an LVEF drop
by >10% points from baseline to <50% LVEF; or cardiac death due to heart
failure, myocardial infarction or arrhythmia, and probable cardiac death
defined as sudden, unexpected death within 24 h of a definite or probable
cardiac event. Grade 4/5 and selected grade 3 nonhematological toxic effects
were defined as any nonhematological adverse drug reaction of grade 4/5
according to NCI CTCAE v3.0 or any of the following grade 3 adverse drug
reactions: palmar-plantar erythrodysesthesia (PPE), cognitive disturbance,
CNS hemorrhage, and mucositis/stomatitis. These toxic effects were
selected because of their assumed relatively high likelihood of occurrence
with this drug combination and their severe impact on the quality of life of
affected patients.
Secondary end points included mild to moderate cardiac toxicity, time to
cardiac toxicity, time to grade 4/5 and selected grade 3 nonhematological
toxicity, overall response [complete response (CR) plus partial response
(PR) as determined by RECIST criteria] [16], time to treatment failure,
duration of response (DR), PFS, OS, and adverse events. Mild to moderate
cardiac toxicity was defined as an LVEF drop by >10% points from baseline
to <50% LVEF, with asymptomatic or only mildly symptomatic
deterioration of cardiac disease (NYHA I–II), confirmed by a second LVEF
assessment after 4 weeks. Time to cardiac toxicity and time to grade 4/5 and
selected grade 3 non-hematological toxicity were calculated from
registration to first documented occurrence.
Before treatment, at the end of cycles 2, 4, and 6, and every 3 cycles
thereafter until disease progression, tumor assessment for objective
response was carried out using computed tomography, magnetic resonance
imaging, or conventional X-ray/ultrasound techniques. Lesions were
assessed using the same method on each occasion. Wherever possible,
lesions were measured or evaluated by the same clinician/radiologist at each
assessment visit. Any objective response (CR or PR) had to be confirmed
after a minimum of 4 weeks.
statistical methods
The statistical design was based on assumptions on the primary end point
of severe cardiac toxicity, and selected grade 3 and grade 4/5 non-
hematological toxicity manifested during the first six treatment cycles (or
until 6 months after enrollment if the treatment had to be stopped before
reaching six cycles). Using Simon’s two-stage optimal design to compute
stage I and stage II sample sizes, a proportion of selected toxic events of
‡33% was considered unacceptable, while £15% was considered acceptable,
in which case, the trial treatment would be proposed for further
investigation. For 5% significance level and 80% power, 14 patients were
needed in the first stage and additional 29 patients for the second stage.
Hence, a maximum of 43 assessable patients were needed.
To allow continuation of patient accrual while waiting for the results of
the stage I analysis, the design was modified by Herndon’s [17] approach.
At final analysis, the treatment would not be considered interesting for
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further investigation, if 9 or more among the 43 patients experienced the
selected toxic events; otherwise the treatment would be considered as
promising for further investigation.
The results were summarized by toxicity rate and 95% Pearson–Clopper
confidence interval (CI).
Patients who discontinued treatment before completing the first two
treatment cycles and who did not experience any of the defined toxic effects
were not considered assessable for the primary end point. For all other end
points, all treated patients (i.e. who received at least one dose of study
medication) were considered assessable. Safety parameters were analyzed
and summarized in tables. Time-to-event end points were assessed at the
end of the trial and estimated by the Kaplan–Meier method. Data analysis
was carried out using SAS 9.1 (SAS Institute Inc., Cary, NC) and S-Plus 8.0
(Insightful Corp., Seattle, WA).
ethical considerations
The trial was carried out in accordance with the declaration of Helsinki, the
Guidelines of the Good Clinical Practice, and the requirements of the local
ethical committees. The respective ethics committees of participating
centers had given approval to the trial. Written informed consent was
obtained from all patients before registration. This study is registered with
ClinicalTrials.gov, number NCT00445406.
results
patients
Between 25 January 2007 and 20 March 2008, 43 patients were
enrolled. Patients’ baseline characteristics are listed in Table 1.
Of the 43 patients, 2 had locally recurrent disease only, all
others had metastatic disease, and 81% and 53% of patients had
received previous hormonal and/or (neo)adjuvant
chemotherapy, respectively. The mean treatment duration was
5.2 months (median 4.3 months, range 0.5–19.4 months), 182
cycles of PLD (median per patient 5, range 1–8) and 247 cycles
of bevacizumab (median per patient 5, range 1–21 months)
were administered. Two patients continued treatment beyond
PD for 3 and 6 months, respectively. PLD had to be reduced,
delayed, or omitted during 109 cycles, almost exclusively due to
toxicity. Bevacizumab had to be delayed or omitted during 61
cycles, mainly due to toxicity (28 cases) or to patients’ request
(15 cases). Median follow-up was 15.0 months.
safety
According to the predefined rules of the Herndon’s approach,
the trial had to be stopped prematurely after the enrollment of
43 patients, although 4 patients did not complete two cycles of
therapy and therefore were not assessable for the primary end
point. Among the 39 fully assessable patients, 16 (41%) had
grade 3 PPE, including 2 patients with additional grade 3
mucositis. One patient (2.3%) had grade 3 mucositis and one
patient (2.3%) had grade 3 cardiac decompensation. Thus, 18
of 39 [46%, 95% CI 30% to 63%] patients were classified as
failures with respect to the primary end point (Table 2).
These toxic events occurred after a median of 2.9 months
(range 1–21 months), 13 of the 17 noncardiac events occurred
before the end of the fifth month of therapy. The only cardiac
toxicity seen in this trial occurred 4.7 months after treatment
initiation. No mild cardiac events occurred. The most frequent
grade 2 toxic effects were PPE (n = 15), mucositis (n = 14),
fatigue (n = 5), hypertension (n = 4), and pain (n = 4). Twenty-
five patients stopped treatment due to PD, nine due to
unacceptable toxic effects of the bevacizumab/PLD
combination therapy, but no patient died during treatment.
Table 1. Patient characteristics at baseline
N (%)
Performance status WHO
0 26 (60)
1 17 (40)
Previous therapies
Surgery 41 (95)
Radiotherapy 35 (81)
(Neo)adjuvant chemotherapy 23 (53)
Hormonal/endocrine 35 (81)
None 1 (2)
Echocardiogram: abnormal findings
Missing 1 (2)
No 34 (79)
Yes 8 (19)
Echocardiogram: description of abnormal findings
Hypertensive cardiac disease 1 (2)
Left ventricular relaxation disturbances but normal
LVEF (57%)
1 (2)
Minimal enlarged left atrium. Minimal mitral valve
insufficiency
1 (2)
Minor aortic insufficiency 1 (2)
Pericardial effusion, not hemodynamically relevant 1 (2)
Relaxation dysfunction 1 (2)
Bicuspid aortic valve, minimal tricuspid insufficiency 1 (2)
NYHA classification
0 36 (84)
1 7 (16)
Hormone receptor status
Negative 9 (21)
Positive 34 (79)
Stage of disease at baseline
Locally recurrent only 2 (5)
Metastatic 41 (95)
Menopausal status
Missing 1 (2)
Premenopausal 4 (9)
Postmenopausal 28 (65)
Other, age <50 2 (5)
Other, age ‡50 8 (19)
LVEF, left ventricular ejection fraction; WHO, World Health Organization
Table 2. Toxicity
Toxicity Patients (total evaluable N = 39), n (%)
Grade 3 PPE 16 (41.0)
Grade 3 mucositis 1 (2.6)
Severe cardiotoxicity 1 (2.6)
Grade 3/4 events 18 (46.2)
PPE, palmar-plantar erythrodysesthesia.
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efficacy
Among the intention-to-treat population of 43 patients, clinical
benefit rate (PR and stable disease) was 73% (31 of 43; 95%
CI 56% to 85%), but only 21% (9 of 43; 95% CI 10% to 36%)
had a PR (Table 3). During follow-up, 32 patients had PD or
died and thus were counted as events for PFS. Nine patients
started second-line treatment without PD and are censored for
this end point, possibly introducing a positive bias. Median
PFS was 5.7 months (95% CI 4.6–8.1; Figure 1). Among the
nine patients with response, the mean response duration was
4.9 months and median time to response was 3.6 months. Since
four of these patients are still without PD, the mean response
duration will increase with continuing follow-up. Eighteen
patients have died, yielding a median OS of 15.9 months
(95% CI 14.0–21.5). The estimated 1-year survival rate is
69% (95% CI 52%–81%).
discussion
There is no generally accepted, optimal first-line chemotherapy
regimen for MBC; however, the use of a taxane and an
anthracycline, either as monotherapy or in combination, is
considered appropriate therapy [18, 19]. Studies comparing
single-agent therapy with combination chemotherapy have
yielded conflicting results [20, 21]. While most of these studies
have shown increases in RR and PFS, and some have even
shown a benefit in OS with combination regimens, toxicity was
generally more severe in the combination therapy [20, 22].
Novel drug combinations that improve efficacy without
additional toxicity are urgently needed. Recently,
antiangiogenic treatment with bevacizumab, a monoclonal
antibody against VEGF, was shown to improve chemotherapy
efficacy in first-line MBC in three large randomized trials [10–
12]. Cardiotoxicity of anthracyclines has been shown to be
increased by several targeted therapies, such as trastuzumab
[24], sunitinib [25], sorafenib [26], and others. When the trial
was planned, there was also concern that bevacizumab might
increase the cardiotoxicity of anthracyclines [13, 15]. These
results prompted our phase II study of bevacizumab with
a cardiac-sparing agent, PLD, that is active in the treatment of
MBC [6, 23].
Results of a randomized trial comparing doxorubicin and
PLD as first-line treatment of women with MBC showed
comparable PFS (7.8 versus 6.9 months) and OS (22 versus 21
months) between treatment arms [6]. The overall RR associated
with PLD was 33% in the 209 patients who had measurable
disease [6]. The RR in our first-line trial of PLD and
bevacizumab in 43 patients with MBC was only 21% and hence
not superior to RRs seen in trials of PLD monotherapy in the
same setting. Similarly, additional phase II trials evaluating
PLD in the second- and third-line MBC setting showed
objective RRs between 13% and 31% [27–29]. The RR in our
trial is disappointing in light of the fact that in all randomized
comparisons of chemotherapy versus chemotherapy plus
bevacizumab in first-line MBC, an increase in RRs was
observed in the combination arms [10–12]. Although cross-
trial differences in patient populations might account for some
of the differences in RR seen, and although our trial was too
small to draw firm conclusions on efficacy, it clearly does not
suggest additive activity of PLD and bevacizumab.
However, the most important finding of our trial was the
relatively high rate of grade 3 PPE (41.0%) and mucositis
(2.6%). PPE is a dermatologic toxicity that occurs relatively
frequently in association with prolonged exposure to cytotoxic
drugs, either because of a relatively long half-life of the drug
(e. g. PLD) or because of continuous application, either orally
(e.g. capecitabine) or by continuous intravenous application
(e.g. 5-fluorouracil, doxorubicin). Although the
pathophysiology of PPE in PLD-treated patients is not well
understood, PLD has been detected in elevated concentrations
in eccrine sweat glands in palms and soles, where it accumulates
perhaps due to the hydrophilic coating of liposomes [30]. The
higher number of eccrine glands in the hands and feet could
explain the preferred localizations of the syndrome.
In two registrational trials of PLD [6, 31], where the dose
of PLD was 50 mg/m2 every 4 weeks, the rate of grade 3 PPE
was 17%–18%. Although in this trial, a lower dose of PLD
(20 mg/m2) administered every 2 weeks was utilized, the rate
of grade 3 PPE was 41%. Indeed, the rate of grade 3–4 PPE
observed in our trial was unusually high relative to other MBC
observational studies (6%–17%) [32, 33].
Despite the relatively small number of patients treated in our
trial and the inherent difficulties of cross-trial comparison, our
findings are suggestive of an additive toxic effect of
bevacizumab and bimonthly PLD with respect to PPE. This
conclusion is also supported by a small trial resulting in dose-
limiting mucositis and skin toxicity in 9 of 12 sarcoma patients
treated with the same schedule of bevacizumab and PLD used
in our trial [14]. Possible mechanisms of action of
Table 3. Best response to bevacizumab/pegylated liposomal doxorubicin
Best response Patients (total evaluable N = 43), n (%)
Partial responses 9 (21.0)
Stable disease 22 (51.2)
Progressive disease 10 (23.3)
Not evaluable 2 (4.6)
Figure 1. Kaplan–Meier curve (including pointwise 95% confidence
interval) showing progression-free survival.
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a hypothetical synergistic toxicity include (i) a direct
pharmacological interaction between PLD and bevacizumab;
(ii) a specific effect of bevacizumab on the vasculature of soles,
palms, and possibly the oral mucosa, leading to increased
accumulation of PLD; and (iii) interference of bevacizumab
with wound healing of dermal and mucosal injuries. It is
notable that the addition of bevacizumab to capecitabine,
a drug with potential antiangiogenic properties that frequently
causes PPE, did not seem to substantially increase PPE in the
randomized RIBBON-1 trial. This suggests a different
interaction of bevacizumab with capecitabine than with PLD or
a different mechanism of capecitabine-induced PPE [12].
In two recent phase I dose escalation studies in advanced
solid tumors, a doubling of the incidence of PPE was reported
after addition of bevacizumab to sorafenib, a raf-kinase
inhibitor, which interferes with the VEGF receptors 1 to 3 and
other kinases [34, 35]. Sorafenib monotherapy is known to
cause PPE in 20% of treated patients, and PPE in these
studies was associated with cumulative sorafenib dose.
However, since no difference in sorafenib serum concentration
between single-agent and dual-drug therapy was demonstrated,
the authors concluded that not a pharmacokinetic interaction
but the anti-VEGF properties of the two drugs must have been
the reason of the synergistic skin toxicity observed [34].
In conclusion, we studied the combination of PLD and
bevacizumab in 43 patients with MBC and observed a high rate
of toxicity with modest activity. Based on these results, we
would not consider the combination of PLD 20 mg/m2 and
bevacizumab 10 mg/kg on days 1 and 15 every 4 weeks, for
further investigation in these patients.
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